Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Overall survival factor in metastatic ccRCC

Thiery-Vuillemin A et al. Clinical Genitourinary Cancer 2018; 16: e297-e305

Key clinical point: Multiple factors must be considered when estimating prognosis in patient pretreated with systemic therapy.

Major finding: Median overall survival [95% confidence interval] was 19.4 months [16.1-24.9]. Three prognostic factors were identified in first-line treatment: Memorial Sloan Kettering Cancer Center (MSKCC) favorable and intermediate risks (hazard ratio [95% confidence interval] = 0.362 [0.207-0.630] and 0.561 [0.393-0.801], respectively, P = 4.10−4), metastasectomy (0.667 [0.468-0.951], P = .03), and lack of lymph node metastasis (0.715 [0.513-0.994], P = .049). In second-line treatment, median OS [95% confidence interval] was 11.0 months [8.9-14.4] for 167 patients. Three different prognostic factors predicted long survival: toxicity for first-line treatment discontinuation (HR [95% confidence interval] = 0.298 [0.180-0.493], P < 10−4), duration of disease control in first-line therapy (0.961 [0.942-0.979], P = 2.10−4), and MSKCC favorable and intermediate risks (0.461 [0.252-0.843] and 0.936 [0.607-1.443], respectively, P = .02)..

Study details: The study included 224 consecutive patients with histologically confirmed metastatic clear cell RCC who received targeted therapy as first-line treatment between January 2007 and March 2015.

Disclosures: The researchers had no relevant financial disclosures.

Citation:

Thiery-Vuillemin A et al. Clinical Genitourinary Cancer 2018; 16: e297-e305